Voyager Therapeutics, Inc.
VYGR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13 | $5 | $6 | $6 |
| % Growth | 157% | -19.7% | 3.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $13 | $5 | $6 | $6 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $36 | $31 | $32 | $36 |
| G&A Expenses | $8 | $10 | $10 | $9 |
| SG&A Expenses | $8 | $10 | $10 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $44 | $42 | $41 | $45 |
| Operating Income | -$31 | -$37 | -$35 | -$38 |
| % Margin | -228.9% | -704.3% | -536% | -610.1% |
| Other Income/Exp. Net | $3 | $3 | $4 | $4 |
| Pre-Tax Income | -$28 | -$33 | -$31 | -$34 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$28 | -$33 | -$31 | -$34 |
| % Margin | -208.7% | -642% | -479.2% | -549.3% |
| EPS | -0.47 | -0.57 | -0.53 | -0.59 |
| % Growth | 17.5% | -7.5% | 10.2% | – |
| EPS Diluted | -0.47 | -0.57 | -0.53 | -0.59 |
| Weighted Avg Shares Out | 59 | 59 | 58 | 58 |
| Weighted Avg Shares Out Dil | 59 | 59 | 58 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $3 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$27 | -$36 | -$34 | -$37 |
| % Margin | -201.1% | -683.8% | -520.3% | -593.9% |